Technique and brand are not the same
Stereotactic radiosurgery, or SRS, is focused radiation rather than an operation. When similar principles are used for body targets, the term stereotactic body radiotherapy may be used. RadiologyInfo, produced by RSNA and ACR, describes gamma-ray and linear-accelerator equipment as different ways to deliver stereotactic treatment.
- Ask what technique is proposed.
- Ask whether the target is intracranial or elsewhere in the body.
- Ask whether treatment is planned in one or more sessions.
- Do not assume a platform name defines eligibility or outcome.
How the platforms differ technically
Gamma Knife directs many focused gamma-ray beams toward an intracranial target. The manufacturer’s Gamma Knife patient information describes brain-focused use, imaging-based planning, and frame or mask immobilization. The FDA CyberKnife device summary describes a robotic linear accelerator with image guidance for stereotactic radiosurgery or precision radiotherapy where radiation treatment is indicated.
- Gamma Knife: dedicated intracranial platform using gamma radiation.
- CyberKnife: robotic linear-accelerator platform using x-rays.
- Current model capabilities and center protocols can differ.
- Regulatory descriptions do not prove comparative effectiveness.
Manufacturer material should be used only for technical description, not superiority or outcome claims.
Intracranial and extracranial use
A brain target may be technically approachable with more than one system, while body treatment requires an appropriate body-capable platform. Even then, the platform label does not answer whether stereotactic treatment is appropriate.
- Exact diagnosis and target location.
- Target size, shape, and number.
- Relationship to critical structures.
- Previous surgery or radiation.
- Movement of the target where relevant.
- Need for fractionation or another technique.
A radiation oncologist, medical physicist, and, when relevant, a neurosurgeon or other specialist should assess the case.
Immobilization, image guidance, and sessions
Gamma Knife treatment may use a head frame or mask depending on the model and plan. Linear-accelerator systems use their own immobilization and image-guidance methods; CyberKnife adds robotic delivery and target-locating features. The number and spacing of sessions are prescribed from the clinical and dosimetric plan.
- What immobilization will be used and why?
- Which imaging defines and verifies the target?
- How is motion managed?
- How many sessions are proposed, and what drives that choice?
- Who checks the plan and machine quality assurance?
Do not infer comfort, accuracy, safety, or effectiveness from the presence or absence of a frame.
Planning quality matters more than a logo
RadiologyInfo describes a multidisciplinary team that can include a radiation oncologist, medical physicist, radiologist, dosimetrist, therapist, nurse, and, for some brain cases, a neurosurgeon or neurologist. The plan defines the target, nearby organs at risk, dose, beam arrangement, and verification.
- Who contours the target and critical structures?
- Who approves the dose prescription and final plan?
- What patient-specific quality checks are performed?
- How does the team review previous radiation?
- How is follow-up imaging interpreted?
- What complication route is available?
A machine brand cannot substitute for an appropriate indication, experienced team, and quality-assured plan.
Ask about adverse effects and recovery
Risks depend on the treated site, diagnosis, dose, fractionation, prior therapy, and individual factors. Ask the treating team to explain likely short- and long-term effects, uncertainty, medicines, follow-up imaging, and which events require urgent evaluation.
- What effects are expected and when?
- What rare but serious risks should be discussed?
- Who answers concerns after treatment?
- What does the discharge plan identify as urgent?
- When will follow-up imaging occur?
- Who decides travel readiness?
The website cannot triage symptoms. A possible emergency or worsening condition requires local emergency services or a licensed clinician.
Prepare a platform-neutral second opinion
Send the same diagnosis, pathology where relevant, imaging, prior treatment records, and radiation summaries to each team. Ask each to explain whether stereotactic treatment is appropriate before asking which machine it would use.
- Clinical indication and alternatives.
- Proposed platform and reason.
- Dose and session approach in general terms.
- Critical structures and prior-treatment constraints.
- Team roles and quality assurance.
- Follow-up and complication plan.
- Case-specific estimate and exclusions.
You may request a coordinated specialist opinion. Virello Health coordinates records and appointments; the radiation team determines eligibility and treatment.
Keep a written decision record
A medical-travel decision is easier to audit when every important answer has an owner, source, and date. Create one record for the radiosurgery platform discussion. Do not copy an answer from another patient, hospital branch, country, or older quote. If information is missing, label it “not yet confirmed” rather than turning an assumption into a fact.
| Planning question | What to ask the treating team | What not to infer |
|---|---|---|
| Diagnosis and treatment intent | What diagnosis is being treated, and is the intent local control, symptom management, or another case-specific objective? | A platform name alone does not reveal the objective or expected benefit. |
| Target and prior treatment | Which target, surrounding structures, previous surgery or radiation, and current imaging affect planning? | A general description of tumor size or location cannot establish suitability. |
| Stereotactic suitability | Is stereotactic radiosurgery or radiotherapy appropriate at all, and what other approaches remain reasonable? | Do not assume the choice is only CyberKnife versus Gamma Knife. The first decision is the clinical approach. |
| Platform rationale | Why does the team propose this platform, immobilization method, image-guidance process, and number of sessions for this case? | Familiar branding, a frameless setup, or a session count is not proof of superior care. |
| Planning and quality roles | Which radiation oncologist, medical physicist, and other specialists contour, plan, check, deliver, and review treatment? | The machine cannot replace multidisciplinary planning or quality assurance. |
| Adverse effects and escalation | Which material effects are relevant to the target and plan, what should prompt contact, and who responds outside scheduled visits? | Do not use a generic online side-effect list as an individual risk estimate or triage tool. |
| Follow-up | Which imaging, reports, dose records, and clinical reviews will be needed after treatment? | A scan schedule from another patient may not apply. The treating team should set follow-up. |
| International handoff | What must be completed before travel home, who decides travel fitness, and which records will the local team receive? | A completed final session does not itself establish fitness to fly or end the need for follow-up. |
Ask each center to answer the same platform-neutral questions. If two recommendations differ, request the clinical and planning reason rather than comparing machine brochures or treating a newer installation as evidence of a better outcome.
Separate each decision by its owner
Several organizations may participate in the journey, but their authority is not interchangeable.
- The radiation oncologist, medical physicist, and relevant specialist assess the medical information, explain reasonable options and risks, obtain informed consent where applicable, plan treatment and follow-up, and decide clinical readiness for travel.
- The hospital confirms the exact facility, appointments, available services, estimate, billing process, records, discharge route, and how unexpected changes are managed.
- The treating center and any travel authority control decisions within their respective scopes. A clinician or coordinator cannot promise an approval.
- Virello Health may coordinate records through the approved intake flow, appointments, written-estimate clarification, and non-clinical travel logistics. It is not the treating provider, insurer, visa authority, airline, or emergency service.
- The patient and family decide whether to proceed after receiving appropriate clinical advice and verified logistical information. They may ask for more time or another opinion when the treating team says that doing so will not create harmful delay.
If two centers favor different platforms, ask their radiation oncologists and medical physicists to explain the case-specific planning reason. A coordinator can obtain summaries and arrange discussion, but cannot decide whether stereotactic treatment is appropriate or which delivery system should be used.
Reconfirm before payment and travel
Use a final dated check rather than assuming earlier information remains current:
- The diagnosis, treatment intent, target, prior treatment, current imaging, and relevant uncertainty are identified.
- The team has first explained whether a stereotactic approach is reasonable and what alternatives remain, rather than only which machine is available.
- The platform, immobilization, image guidance, session plan, and clinical rationale are described without superiority claims.
- Radiation-oncology, medical-physics, planning, quality-check, and follow-up responsibilities are clear.
- Material adverse effects, escalation contacts, and post-treatment review have been discussed for the proposed plan.
- The estimate corresponds to the actual planning and delivery pathway rather than a generic platform price.
- Dose records, images, reports, and home-team follow-up are arranged.
- The treating clinician will decide discharge and travel readiness; completing treatment is not automatic clearance.
Save this record outside the blog and update it whenever the clinical plan, estimate, official rule, or travel schedule changes.
Ask for a platform-neutral treatment summary
Before comparing centers, ask each radiation team for a written summary that can be understood without marketing material. It should identify the diagnosis and treatment intent, target and relevant prior treatment, why a stereotactic approach is being considered, which alternatives were discussed, and what information remains uncertain.
For the proposed plan, ask the team to record:
- The platform and the clinical reason it was selected.
- The immobilization and image-guidance approach in plain language.
- Who performs contouring, planning, physics checks, delivery, and clinical review.
- Whether treatment is proposed in one or multiple sessions and why that schedule is being considered.
- Which material adverse effects and escalation contacts were discussed for the case.
- What records, dose information, images, and follow-up instructions will be supplied.
- What must happen before the treating clinician can decide discharge and travel readiness.
This summary does not need to disclose proprietary planning details, and it cannot predict an individual outcome. Its purpose is to show the clinical logic around the machine. If one center answers only with claims about precision, comfort, speed, or technological superiority, the comparison is still incomplete.
When recommendations differ, ask whether the difference comes from diagnosis, target definition, previous treatment, treatment intent, institutional workflow, platform availability, or a genuinely reasonable planning choice. A radiation oncologist and medical physicist should interpret those differences; a coordinator can organize the questions but cannot choose the platform.
Continue planning
- Use the cancer second-opinion guide when diagnosis, planning, or platform recommendations differ.
- Review another specialist oncology pathway in the CAR-T cell therapy in India guide.
- Prepare the cross-border journey with the medical tourism in India planning checklist.
